Tango Therapeutics/$TNGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Ticker
$TNGX
Sector
Primary listing
Employees
155
Headquarters
Website
TNGX Metrics
BasicAdvanced
$1.1B
-
-$0.91
1.75
-
Price and volume
Market cap
$1.1B
Beta
1.75
52-week high
$9.70
52-week low
$1.03
Average daily volume
3.6M
Financial strength
Current ratio
8.88
Quick ratio
8.285
Long term debt to equity
19.784
Total debt to equity
21.723
Profitability
EBITDA (TTM)
-107.913
Gross margin (TTM)
-101.50%
Net profit margin (TTM)
-151.15%
Operating margin (TTM)
-165.91%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-24.52%
Return on equity (TTM)
-51.65%
Valuation
Price to revenue (TTM)
13.316
Price to book
5.58
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
-6.034
Free cash flow yield (TTM)
-16.57%
Free cash flow per share (TTM)
-1.328
Growth
Revenue change (TTM)
53.29%
Earnings per share change (TTM)
-20.31%
3-year revenue growth (CAGR)
40.14%
3-year earnings per share growth (CAGR)
-7.45%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Bulls say / Bears say
In November 2025, vopimetostat (TNG462) demonstrated a median progression-free survival of 7.2 months in second-line MTAP-deleted pancreatic cancer, supporting planned pivotal studies in 2026. (GlobeNewswire)
Tango dosed the first patient in its Phase 1/2 combination trial of TNG462 with Revolution Medicines’ daraxonrasib and zoldonrasib, advancing synergistic therapeutic approaches for MTAP-deleted, RAS-mutant cancers. (GlobeNewswire)
An October 2025 financing raised $225 million in gross proceeds, extending Tango’s cash runway into 2028 and funding upcoming registrational and combination studies. (GlobeNewswire)
In Q1 2025, Tango reported a net loss of $39.9 million and extended its cash runway into Q1 2027 by cutting preclinical spending, highlighting ongoing cash burn challenges. (GlobeNewswire)
The October 2025 equity offering involved issuing over 21 million new shares and pre-funded warrants, posing significant dilution risk to existing shareholders. (GlobeNewswire)
Key clinical data updates for TNG462 monotherapy and combination trials are not expected until H2 2025 and 2026, indicating a lack of near-term registrational readouts. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
TNGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $1.1B as of November 08, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of November 08, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.